Taysha Gene Therapies (TSHA): BofA Sees 214% Price Potential - TSHA-102 Could Achieve Risk-Adjusted Peak Revenue of $995 Million by 2031!

On May 28, Taysha Gene Therapies (TSHA) reported that it has made significant progress in the development of TSHA-102. This is a gene therapy treatment for Rett syndrome. The Phase 1/2 studies, known as REVEAL, were conducted in two parts: Part A focused on dose finding, while Part B aims to evaluate the efficacy and safety in an expanded patient population. In February 2025, the company reported that the treatment with TSHA-102 was well tolerated in both low and high doses, without any serious treatment-related side effects or dose-limiting toxicities...